Medical Care
Global Endocrinology and Metabolism Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 573980
- Pages: 131
- Figures: 145
- Views: 9
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Endocrinology and Metabolism market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Abbott Laboratories
Acerus Pharmaceuticals Corp.
Ascendis Pharma AS
Bayer AG
Beta Cell NV
Biocon Ltd.
Eli Lilly and Co.
Endo International Plc
Hoffmann La Roche Ltd.
GlaxoSmithKline Plc
Hanmi Pharm Co. Ltd.
Ipsen Pharma
Segment by Type
Diabetes Drugs
HGH
Thyroid Hormone Disorders
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Endocrinology and Metabolism study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Endocrinology and Metabolism market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Abbott Laboratories
Acerus Pharmaceuticals Corp.
Ascendis Pharma AS
Bayer AG
Beta Cell NV
Biocon Ltd.
Eli Lilly and Co.
Endo International Plc
Hoffmann La Roche Ltd.
GlaxoSmithKline Plc
Hanmi Pharm Co. Ltd.
Ipsen Pharma
Segment by Type
Diabetes Drugs
HGH
Thyroid Hormone Disorders
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Endocrinology and Metabolism study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Endocrinology and Metabolism: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Endocrinology and Metabolism Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Diabetes Drugs
1.2.3 HGH
1.2.4 Thyroid Hormone Disorders
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Endocrinology and Metabolism Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Endocrinology and Metabolism Revenue Estimates and Forecasts 2020-2031
2.2 Global Endocrinology and Metabolism Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Endocrinology and Metabolism Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Endocrinology and Metabolism Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Diabetes Drugs Market Size by Players
3.3.2 HGH Market Size by Players
3.3.3 Thyroid Hormone Disorders Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Endocrinology and Metabolism Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Endocrinology and Metabolism Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Endocrinology and Metabolism Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Endocrinology and Metabolism Market Size by Type (2020-2031)
6.4 North America Endocrinology and Metabolism Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Endocrinology and Metabolism Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Endocrinology and Metabolism Market Size by Type (2020-2031)
7.4 Europe Endocrinology and Metabolism Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Endocrinology and Metabolism Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Endocrinology and Metabolism Market Size by Type (2020-2031)
8.4 Asia-Pacific Endocrinology and Metabolism Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Endocrinology and Metabolism Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Endocrinology and Metabolism Market Size by Type (2020-2031)
9.4 Central and South America Endocrinology and Metabolism Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Endocrinology and Metabolism Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Endocrinology and Metabolism Market Size by Type (2020-2031)
10.4 Middle East and Africa Endocrinology and Metabolism Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Endocrinology and Metabolism Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Corporation Information
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Endocrinology and Metabolism Product Features and Attributes
11.1.4 Abbott Laboratories Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.1.5 Abbott Laboratories Endocrinology and Metabolism Revenue by Product in 2024
11.1.6 Abbott Laboratories Endocrinology and Metabolism Revenue by Application in 2024
11.1.7 Abbott Laboratories Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.1.8 Abbott Laboratories Endocrinology and Metabolism SWOT Analysis
11.1.9 Abbott Laboratories Recent Developments
11.2 Acerus Pharmaceuticals Corp.
11.2.1 Acerus Pharmaceuticals Corp. Corporation Information
11.2.2 Acerus Pharmaceuticals Corp. Business Overview
11.2.3 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Product Features and Attributes
11.2.4 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.2.5 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Revenue by Product in 2024
11.2.6 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Revenue by Application in 2024
11.2.7 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.2.8 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism SWOT Analysis
11.2.9 Acerus Pharmaceuticals Corp. Recent Developments
11.3 Ascendis Pharma AS
11.3.1 Ascendis Pharma AS Corporation Information
11.3.2 Ascendis Pharma AS Business Overview
11.3.3 Ascendis Pharma AS Endocrinology and Metabolism Product Features and Attributes
11.3.4 Ascendis Pharma AS Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.3.5 Ascendis Pharma AS Endocrinology and Metabolism Revenue by Product in 2024
11.3.6 Ascendis Pharma AS Endocrinology and Metabolism Revenue by Application in 2024
11.3.7 Ascendis Pharma AS Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.3.8 Ascendis Pharma AS Endocrinology and Metabolism SWOT Analysis
11.3.9 Ascendis Pharma AS Recent Developments
11.4 Bayer AG
11.4.1 Bayer AG Corporation Information
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Endocrinology and Metabolism Product Features and Attributes
11.4.4 Bayer AG Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.4.5 Bayer AG Endocrinology and Metabolism Revenue by Product in 2024
11.4.6 Bayer AG Endocrinology and Metabolism Revenue by Application in 2024
11.4.7 Bayer AG Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.4.8 Bayer AG Endocrinology and Metabolism SWOT Analysis
11.4.9 Bayer AG Recent Developments
11.5 Beta Cell NV
11.5.1 Beta Cell NV Corporation Information
11.5.2 Beta Cell NV Business Overview
11.5.3 Beta Cell NV Endocrinology and Metabolism Product Features and Attributes
11.5.4 Beta Cell NV Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.5.5 Beta Cell NV Endocrinology and Metabolism Revenue by Product in 2024
11.5.6 Beta Cell NV Endocrinology and Metabolism Revenue by Application in 2024
11.5.7 Beta Cell NV Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.5.8 Beta Cell NV Endocrinology and Metabolism SWOT Analysis
11.5.9 Beta Cell NV Recent Developments
11.6 Biocon Ltd.
11.6.1 Biocon Ltd. Corporation Information
11.6.2 Biocon Ltd. Business Overview
11.6.3 Biocon Ltd. Endocrinology and Metabolism Product Features and Attributes
11.6.4 Biocon Ltd. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.6.5 Biocon Ltd. Recent Developments
11.7 Eli Lilly and Co.
11.7.1 Eli Lilly and Co. Corporation Information
11.7.2 Eli Lilly and Co. Business Overview
11.7.3 Eli Lilly and Co. Endocrinology and Metabolism Product Features and Attributes
11.7.4 Eli Lilly and Co. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.7.5 Eli Lilly and Co. Recent Developments
11.8 Endo International Plc
11.8.1 Endo International Plc Corporation Information
11.8.2 Endo International Plc Business Overview
11.8.3 Endo International Plc Endocrinology and Metabolism Product Features and Attributes
11.8.4 Endo International Plc Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.8.5 Endo International Plc Recent Developments
11.9 Hoffmann La Roche Ltd.
11.9.1 Hoffmann La Roche Ltd. Corporation Information
11.9.2 Hoffmann La Roche Ltd. Business Overview
11.9.3 Hoffmann La Roche Ltd. Endocrinology and Metabolism Product Features and Attributes
11.9.4 Hoffmann La Roche Ltd. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.9.5 Hoffmann La Roche Ltd. Recent Developments
11.10 GlaxoSmithKline Plc
11.10.1 GlaxoSmithKline Plc Corporation Information
11.10.2 GlaxoSmithKline Plc Business Overview
11.10.3 GlaxoSmithKline Plc Endocrinology and Metabolism Product Features and Attributes
11.10.4 GlaxoSmithKline Plc Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Hanmi Pharm Co. Ltd.
11.11.1 Hanmi Pharm Co. Ltd. Corporation Information
11.11.2 Hanmi Pharm Co. Ltd. Business Overview
11.11.3 Hanmi Pharm Co. Ltd. Endocrinology and Metabolism Product Features and Attributes
11.11.4 Hanmi Pharm Co. Ltd. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.11.5 Hanmi Pharm Co. Ltd. Recent Developments
11.12 Ipsen Pharma
11.12.1 Ipsen Pharma Corporation Information
11.12.2 Ipsen Pharma Business Overview
11.12.3 Ipsen Pharma Endocrinology and Metabolism Product Features and Attributes
11.12.4 Ipsen Pharma Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.12.5 Ipsen Pharma Recent Developments
12 Endocrinology and MetabolismIndustry Chain Analysis
12.1 Endocrinology and Metabolism Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Endocrinology and Metabolism Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Endocrinology and Metabolism Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Endocrinology and Metabolism: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Endocrinology and Metabolism Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Diabetes Drugs
1.2.3 HGH
1.2.4 Thyroid Hormone Disorders
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Endocrinology and Metabolism Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Endocrinology and Metabolism Revenue Estimates and Forecasts 2020-2031
2.2 Global Endocrinology and Metabolism Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Endocrinology and Metabolism Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Endocrinology and Metabolism Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Diabetes Drugs Market Size by Players
3.3.2 HGH Market Size by Players
3.3.3 Thyroid Hormone Disorders Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Endocrinology and Metabolism Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Endocrinology and Metabolism Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Endocrinology and Metabolism Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Endocrinology and Metabolism Market Size by Type (2020-2031)
6.4 North America Endocrinology and Metabolism Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Endocrinology and Metabolism Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Endocrinology and Metabolism Market Size by Type (2020-2031)
7.4 Europe Endocrinology and Metabolism Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Endocrinology and Metabolism Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Endocrinology and Metabolism Market Size by Type (2020-2031)
8.4 Asia-Pacific Endocrinology and Metabolism Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Endocrinology and Metabolism Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Endocrinology and Metabolism Market Size by Type (2020-2031)
9.4 Central and South America Endocrinology and Metabolism Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Endocrinology and Metabolism Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Endocrinology and Metabolism Market Size by Type (2020-2031)
10.4 Middle East and Africa Endocrinology and Metabolism Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Endocrinology and Metabolism Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Corporation Information
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Endocrinology and Metabolism Product Features and Attributes
11.1.4 Abbott Laboratories Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.1.5 Abbott Laboratories Endocrinology and Metabolism Revenue by Product in 2024
11.1.6 Abbott Laboratories Endocrinology and Metabolism Revenue by Application in 2024
11.1.7 Abbott Laboratories Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.1.8 Abbott Laboratories Endocrinology and Metabolism SWOT Analysis
11.1.9 Abbott Laboratories Recent Developments
11.2 Acerus Pharmaceuticals Corp.
11.2.1 Acerus Pharmaceuticals Corp. Corporation Information
11.2.2 Acerus Pharmaceuticals Corp. Business Overview
11.2.3 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Product Features and Attributes
11.2.4 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.2.5 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Revenue by Product in 2024
11.2.6 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Revenue by Application in 2024
11.2.7 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.2.8 Acerus Pharmaceuticals Corp. Endocrinology and Metabolism SWOT Analysis
11.2.9 Acerus Pharmaceuticals Corp. Recent Developments
11.3 Ascendis Pharma AS
11.3.1 Ascendis Pharma AS Corporation Information
11.3.2 Ascendis Pharma AS Business Overview
11.3.3 Ascendis Pharma AS Endocrinology and Metabolism Product Features and Attributes
11.3.4 Ascendis Pharma AS Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.3.5 Ascendis Pharma AS Endocrinology and Metabolism Revenue by Product in 2024
11.3.6 Ascendis Pharma AS Endocrinology and Metabolism Revenue by Application in 2024
11.3.7 Ascendis Pharma AS Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.3.8 Ascendis Pharma AS Endocrinology and Metabolism SWOT Analysis
11.3.9 Ascendis Pharma AS Recent Developments
11.4 Bayer AG
11.4.1 Bayer AG Corporation Information
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Endocrinology and Metabolism Product Features and Attributes
11.4.4 Bayer AG Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.4.5 Bayer AG Endocrinology and Metabolism Revenue by Product in 2024
11.4.6 Bayer AG Endocrinology and Metabolism Revenue by Application in 2024
11.4.7 Bayer AG Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.4.8 Bayer AG Endocrinology and Metabolism SWOT Analysis
11.4.9 Bayer AG Recent Developments
11.5 Beta Cell NV
11.5.1 Beta Cell NV Corporation Information
11.5.2 Beta Cell NV Business Overview
11.5.3 Beta Cell NV Endocrinology and Metabolism Product Features and Attributes
11.5.4 Beta Cell NV Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.5.5 Beta Cell NV Endocrinology and Metabolism Revenue by Product in 2024
11.5.6 Beta Cell NV Endocrinology and Metabolism Revenue by Application in 2024
11.5.7 Beta Cell NV Endocrinology and Metabolism Revenue by Geographic Area in 2024
11.5.8 Beta Cell NV Endocrinology and Metabolism SWOT Analysis
11.5.9 Beta Cell NV Recent Developments
11.6 Biocon Ltd.
11.6.1 Biocon Ltd. Corporation Information
11.6.2 Biocon Ltd. Business Overview
11.6.3 Biocon Ltd. Endocrinology and Metabolism Product Features and Attributes
11.6.4 Biocon Ltd. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.6.5 Biocon Ltd. Recent Developments
11.7 Eli Lilly and Co.
11.7.1 Eli Lilly and Co. Corporation Information
11.7.2 Eli Lilly and Co. Business Overview
11.7.3 Eli Lilly and Co. Endocrinology and Metabolism Product Features and Attributes
11.7.4 Eli Lilly and Co. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.7.5 Eli Lilly and Co. Recent Developments
11.8 Endo International Plc
11.8.1 Endo International Plc Corporation Information
11.8.2 Endo International Plc Business Overview
11.8.3 Endo International Plc Endocrinology and Metabolism Product Features and Attributes
11.8.4 Endo International Plc Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.8.5 Endo International Plc Recent Developments
11.9 Hoffmann La Roche Ltd.
11.9.1 Hoffmann La Roche Ltd. Corporation Information
11.9.2 Hoffmann La Roche Ltd. Business Overview
11.9.3 Hoffmann La Roche Ltd. Endocrinology and Metabolism Product Features and Attributes
11.9.4 Hoffmann La Roche Ltd. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.9.5 Hoffmann La Roche Ltd. Recent Developments
11.10 GlaxoSmithKline Plc
11.10.1 GlaxoSmithKline Plc Corporation Information
11.10.2 GlaxoSmithKline Plc Business Overview
11.10.3 GlaxoSmithKline Plc Endocrinology and Metabolism Product Features and Attributes
11.10.4 GlaxoSmithKline Plc Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Hanmi Pharm Co. Ltd.
11.11.1 Hanmi Pharm Co. Ltd. Corporation Information
11.11.2 Hanmi Pharm Co. Ltd. Business Overview
11.11.3 Hanmi Pharm Co. Ltd. Endocrinology and Metabolism Product Features and Attributes
11.11.4 Hanmi Pharm Co. Ltd. Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.11.5 Hanmi Pharm Co. Ltd. Recent Developments
11.12 Ipsen Pharma
11.12.1 Ipsen Pharma Corporation Information
11.12.2 Ipsen Pharma Business Overview
11.12.3 Ipsen Pharma Endocrinology and Metabolism Product Features and Attributes
11.12.4 Ipsen Pharma Endocrinology and Metabolism Revenue and Gross Margin (2020-2025)
11.12.5 Ipsen Pharma Recent Developments
12 Endocrinology and MetabolismIndustry Chain Analysis
12.1 Endocrinology and Metabolism Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Endocrinology and Metabolism Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Endocrinology and Metabolism Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Endocrinology and Metabolism Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Endocrinology and Metabolism Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Endocrinology and Metabolism Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Endocrinology and Metabolism Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Endocrinology and Metabolism Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Endocrinology and Metabolism Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Endocrinology and Metabolism by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endocrinology and Metabolism as of 2024)
Table 11. Global Endocrinology and Metabolism Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Endocrinology and Metabolism Companies Headquarters
Table 13. Global Endocrinology and Metabolism Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Endocrinology and Metabolism Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Endocrinology and Metabolism Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Endocrinology and Metabolism Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Endocrinology and Metabolism Revenue by Application (2026-2031) & (US$ Million)
Table 21. Endocrinology and Metabolism High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Endocrinology and Metabolism Growth Accelerators and Market Barriers
Table 25. North America Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Endocrinology and Metabolism Growth Accelerators and Market Barriers
Table 27. Europe Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Endocrinology and Metabolism Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Endocrinology and Metabolism Investment Opportunities and Key Challenges
Table 31. Central and South America Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Endocrinology and Metabolism Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Abbott Laboratories Corporation Information
Table 35. Abbott Laboratories Description and Major Businesses
Table 36. Abbott Laboratories Product Features and Attributes
Table 37. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Abbott Laboratories Revenue Proportion by Product in 2024
Table 39. Abbott Laboratories Revenue Proportion by Application in 2024
Table 40. Abbott Laboratories Revenue Proportion by Geographic Area in 2024
Table 41. Abbott Laboratories Endocrinology and Metabolism SWOT Analysis
Table 42. Abbott Laboratories Recent Developments
Table 43. Acerus Pharmaceuticals Corp. Corporation Information
Table 44. Acerus Pharmaceuticals Corp. Description and Major Businesses
Table 45. Acerus Pharmaceuticals Corp. Product Features and Attributes
Table 46. Acerus Pharmaceuticals Corp. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Acerus Pharmaceuticals Corp. Revenue Proportion by Product in 2024
Table 48. Acerus Pharmaceuticals Corp. Revenue Proportion by Application in 2024
Table 49. Acerus Pharmaceuticals Corp. Revenue Proportion by Geographic Area in 2024
Table 50. Acerus Pharmaceuticals Corp. Endocrinology and Metabolism SWOT Analysis
Table 51. Acerus Pharmaceuticals Corp. Recent Developments
Table 52. Ascendis Pharma AS Corporation Information
Table 53. Ascendis Pharma AS Description and Major Businesses
Table 54. Ascendis Pharma AS Product Features and Attributes
Table 55. Ascendis Pharma AS Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Ascendis Pharma AS Revenue Proportion by Product in 2024
Table 57. Ascendis Pharma AS Revenue Proportion by Application in 2024
Table 58. Ascendis Pharma AS Revenue Proportion by Geographic Area in 2024
Table 59. Ascendis Pharma AS Endocrinology and Metabolism SWOT Analysis
Table 60. Ascendis Pharma AS Recent Developments
Table 61. Bayer AG Corporation Information
Table 62. Bayer AG Description and Major Businesses
Table 63. Bayer AG Product Features and Attributes
Table 64. Bayer AG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Bayer AG Revenue Proportion by Product in 2024
Table 66. Bayer AG Revenue Proportion by Application in 2024
Table 67. Bayer AG Revenue Proportion by Geographic Area in 2024
Table 68. Bayer AG Endocrinology and Metabolism SWOT Analysis
Table 69. Bayer AG Recent Developments
Table 70. Beta Cell NV Corporation Information
Table 71. Beta Cell NV Description and Major Businesses
Table 72. Beta Cell NV Product Features and Attributes
Table 73. Beta Cell NV Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Beta Cell NV Revenue Proportion by Product in 2024
Table 75. Beta Cell NV Revenue Proportion by Application in 2024
Table 76. Beta Cell NV Revenue Proportion by Geographic Area in 2024
Table 77. Beta Cell NV Endocrinology and Metabolism SWOT Analysis
Table 78. Beta Cell NV Recent Developments
Table 79. Biocon Ltd. Corporation Information
Table 80. Biocon Ltd. Description and Major Businesses
Table 81. Biocon Ltd. Product Features and Attributes
Table 82. Biocon Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Biocon Ltd. Recent Developments
Table 84. Eli Lilly and Co. Corporation Information
Table 85. Eli Lilly and Co. Description and Major Businesses
Table 86. Eli Lilly and Co. Product Features and Attributes
Table 87. Eli Lilly and Co. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Eli Lilly and Co. Recent Developments
Table 89. Endo International Plc Corporation Information
Table 90. Endo International Plc Description and Major Businesses
Table 91. Endo International Plc Product Features and Attributes
Table 92. Endo International Plc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Endo International Plc Recent Developments
Table 94. Hoffmann La Roche Ltd. Corporation Information
Table 95. Hoffmann La Roche Ltd. Description and Major Businesses
Table 96. Hoffmann La Roche Ltd. Product Features and Attributes
Table 97. Hoffmann La Roche Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Hoffmann La Roche Ltd. Recent Developments
Table 99. GlaxoSmithKline Plc Corporation Information
Table 100. GlaxoSmithKline Plc Description and Major Businesses
Table 101. GlaxoSmithKline Plc Product Features and Attributes
Table 102. GlaxoSmithKline Plc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. GlaxoSmithKline Plc Recent Developments
Table 104. Hanmi Pharm Co. Ltd. Corporation Information
Table 105. Hanmi Pharm Co. Ltd. Description and Major Businesses
Table 106. Hanmi Pharm Co. Ltd. Product Features and Attributes
Table 107. Hanmi Pharm Co. Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Hanmi Pharm Co. Ltd. Recent Developments
Table 109. Ipsen Pharma Corporation Information
Table 110. Ipsen Pharma Description and Major Businesses
Table 111. Ipsen Pharma Product Features and Attributes
Table 112. Ipsen Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Ipsen Pharma Recent Developments
Table 114. Raw Materials Key Suppliers
Table 115. Distributors List
Table 116. Market Trends and Market Evolution
Table 117. Market Drivers and Opportunities
Table 118. Market Challenges, Risks, and Restraints
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Endocrinology and Metabolism Product Picture
Figure 2. Global Endocrinology and Metabolism Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Diabetes Drugs Product Picture
Figure 4. HGH Product Picture
Figure 5. Thyroid Hormone Disorders Product Picture
Figure 6. Others Product Picture
Figure 7. Global Endocrinology and Metabolism Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Endocrinology and Metabolism Report Years Considered
Figure 12. Global Endocrinology and Metabolism Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 14. Global Endocrinology and Metabolism Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Endocrinology and Metabolism Revenue Market Share by Region (2020-2031)
Figure 16. Global Endocrinology and Metabolism Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Diabetes Drugs Revenue Market Share by Player in 2024
Figure 19. HGH Revenue Market Share by Player in 2024
Figure 20. Thyroid Hormone Disorders Revenue Market Share by Player in 2024
Figure 21. Others Revenue Market Share by Player in 2024
Figure 22. Global Endocrinology and Metabolism Revenue Market Share by Type (2020-2031)
Figure 23. Global Endocrinology and Metabolism Revenue Market Share by Application (2020-2031)
Figure 24. North America Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 26. North America Endocrinology and Metabolism Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 33. Europe Endocrinology and Metabolism Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 36. France Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Endocrinology and Metabolism Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 48. India Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 56. Central and South America Endocrinology and Metabolism Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 62. South America Endocrinology and Metabolism Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 68. Endocrinology and Metabolism Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Table 1. Global Endocrinology and Metabolism Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Endocrinology and Metabolism Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Endocrinology and Metabolism Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Endocrinology and Metabolism Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Endocrinology and Metabolism Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Endocrinology and Metabolism Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Endocrinology and Metabolism by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endocrinology and Metabolism as of 2024)
Table 11. Global Endocrinology and Metabolism Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Endocrinology and Metabolism Companies Headquarters
Table 13. Global Endocrinology and Metabolism Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Endocrinology and Metabolism Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Endocrinology and Metabolism Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Endocrinology and Metabolism Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Endocrinology and Metabolism Revenue by Application (2026-2031) & (US$ Million)
Table 21. Endocrinology and Metabolism High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Endocrinology and Metabolism Growth Accelerators and Market Barriers
Table 25. North America Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Endocrinology and Metabolism Growth Accelerators and Market Barriers
Table 27. Europe Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Endocrinology and Metabolism Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Endocrinology and Metabolism Investment Opportunities and Key Challenges
Table 31. Central and South America Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Endocrinology and Metabolism Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Endocrinology and Metabolism Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Abbott Laboratories Corporation Information
Table 35. Abbott Laboratories Description and Major Businesses
Table 36. Abbott Laboratories Product Features and Attributes
Table 37. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Abbott Laboratories Revenue Proportion by Product in 2024
Table 39. Abbott Laboratories Revenue Proportion by Application in 2024
Table 40. Abbott Laboratories Revenue Proportion by Geographic Area in 2024
Table 41. Abbott Laboratories Endocrinology and Metabolism SWOT Analysis
Table 42. Abbott Laboratories Recent Developments
Table 43. Acerus Pharmaceuticals Corp. Corporation Information
Table 44. Acerus Pharmaceuticals Corp. Description and Major Businesses
Table 45. Acerus Pharmaceuticals Corp. Product Features and Attributes
Table 46. Acerus Pharmaceuticals Corp. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Acerus Pharmaceuticals Corp. Revenue Proportion by Product in 2024
Table 48. Acerus Pharmaceuticals Corp. Revenue Proportion by Application in 2024
Table 49. Acerus Pharmaceuticals Corp. Revenue Proportion by Geographic Area in 2024
Table 50. Acerus Pharmaceuticals Corp. Endocrinology and Metabolism SWOT Analysis
Table 51. Acerus Pharmaceuticals Corp. Recent Developments
Table 52. Ascendis Pharma AS Corporation Information
Table 53. Ascendis Pharma AS Description and Major Businesses
Table 54. Ascendis Pharma AS Product Features and Attributes
Table 55. Ascendis Pharma AS Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Ascendis Pharma AS Revenue Proportion by Product in 2024
Table 57. Ascendis Pharma AS Revenue Proportion by Application in 2024
Table 58. Ascendis Pharma AS Revenue Proportion by Geographic Area in 2024
Table 59. Ascendis Pharma AS Endocrinology and Metabolism SWOT Analysis
Table 60. Ascendis Pharma AS Recent Developments
Table 61. Bayer AG Corporation Information
Table 62. Bayer AG Description and Major Businesses
Table 63. Bayer AG Product Features and Attributes
Table 64. Bayer AG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Bayer AG Revenue Proportion by Product in 2024
Table 66. Bayer AG Revenue Proportion by Application in 2024
Table 67. Bayer AG Revenue Proportion by Geographic Area in 2024
Table 68. Bayer AG Endocrinology and Metabolism SWOT Analysis
Table 69. Bayer AG Recent Developments
Table 70. Beta Cell NV Corporation Information
Table 71. Beta Cell NV Description and Major Businesses
Table 72. Beta Cell NV Product Features and Attributes
Table 73. Beta Cell NV Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Beta Cell NV Revenue Proportion by Product in 2024
Table 75. Beta Cell NV Revenue Proportion by Application in 2024
Table 76. Beta Cell NV Revenue Proportion by Geographic Area in 2024
Table 77. Beta Cell NV Endocrinology and Metabolism SWOT Analysis
Table 78. Beta Cell NV Recent Developments
Table 79. Biocon Ltd. Corporation Information
Table 80. Biocon Ltd. Description and Major Businesses
Table 81. Biocon Ltd. Product Features and Attributes
Table 82. Biocon Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Biocon Ltd. Recent Developments
Table 84. Eli Lilly and Co. Corporation Information
Table 85. Eli Lilly and Co. Description and Major Businesses
Table 86. Eli Lilly and Co. Product Features and Attributes
Table 87. Eli Lilly and Co. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Eli Lilly and Co. Recent Developments
Table 89. Endo International Plc Corporation Information
Table 90. Endo International Plc Description and Major Businesses
Table 91. Endo International Plc Product Features and Attributes
Table 92. Endo International Plc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Endo International Plc Recent Developments
Table 94. Hoffmann La Roche Ltd. Corporation Information
Table 95. Hoffmann La Roche Ltd. Description and Major Businesses
Table 96. Hoffmann La Roche Ltd. Product Features and Attributes
Table 97. Hoffmann La Roche Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Hoffmann La Roche Ltd. Recent Developments
Table 99. GlaxoSmithKline Plc Corporation Information
Table 100. GlaxoSmithKline Plc Description and Major Businesses
Table 101. GlaxoSmithKline Plc Product Features and Attributes
Table 102. GlaxoSmithKline Plc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. GlaxoSmithKline Plc Recent Developments
Table 104. Hanmi Pharm Co. Ltd. Corporation Information
Table 105. Hanmi Pharm Co. Ltd. Description and Major Businesses
Table 106. Hanmi Pharm Co. Ltd. Product Features and Attributes
Table 107. Hanmi Pharm Co. Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Hanmi Pharm Co. Ltd. Recent Developments
Table 109. Ipsen Pharma Corporation Information
Table 110. Ipsen Pharma Description and Major Businesses
Table 111. Ipsen Pharma Product Features and Attributes
Table 112. Ipsen Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Ipsen Pharma Recent Developments
Table 114. Raw Materials Key Suppliers
Table 115. Distributors List
Table 116. Market Trends and Market Evolution
Table 117. Market Drivers and Opportunities
Table 118. Market Challenges, Risks, and Restraints
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Endocrinology and Metabolism Product Picture
Figure 2. Global Endocrinology and Metabolism Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Diabetes Drugs Product Picture
Figure 4. HGH Product Picture
Figure 5. Thyroid Hormone Disorders Product Picture
Figure 6. Others Product Picture
Figure 7. Global Endocrinology and Metabolism Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Endocrinology and Metabolism Report Years Considered
Figure 12. Global Endocrinology and Metabolism Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 14. Global Endocrinology and Metabolism Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Endocrinology and Metabolism Revenue Market Share by Region (2020-2031)
Figure 16. Global Endocrinology and Metabolism Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Diabetes Drugs Revenue Market Share by Player in 2024
Figure 19. HGH Revenue Market Share by Player in 2024
Figure 20. Thyroid Hormone Disorders Revenue Market Share by Player in 2024
Figure 21. Others Revenue Market Share by Player in 2024
Figure 22. Global Endocrinology and Metabolism Revenue Market Share by Type (2020-2031)
Figure 23. Global Endocrinology and Metabolism Revenue Market Share by Application (2020-2031)
Figure 24. North America Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 26. North America Endocrinology and Metabolism Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 33. Europe Endocrinology and Metabolism Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 36. France Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Endocrinology and Metabolism Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 48. India Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Endocrinology and Metabolism Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 56. Central and South America Endocrinology and Metabolism Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Endocrinology and Metabolism Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Endocrinology and Metabolism Revenue (US$ Million) in 2024
Figure 62. South America Endocrinology and Metabolism Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Endocrinology and Metabolism Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Endocrinology and Metabolism Revenue (2020-2025) & (US$ Million)
Figure 68. Endocrinology and Metabolism Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232